Open AccessPoly-2-methyl-2-oxazoline–modified bioprosthetic heart valve leaflets have enhanced biocompatibility and resist structural degeneration
Author(s) -
Andrey Zakharchenko,
Yuanyuan Xue,
Samuel Keeney,
Christopher A Rock,
Ivan S. Alferiev,
Stanley J. Stachelek,
Hajime Takano,
T. Thomas,
Chandrasekaran Nagaswami,
Abba M. Krieger,
Michael Chorny,
Giovanni Ferrari,
Robert J. Levy
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2120694119
Subject(s) - calcification , chemistry , medicine
Significance Heart valve disease affects millions, and since there is no effective medical therapy, surgical repair when possible—or more commonly, replacement—are the only treatments available. Bioprosthetic heart valves (BHV), the most frequently used valve replacements, are composed of heterograft tissue, typically fixed in glutaraldehyde, and prepared for human use either as surgically implantable devices or for transcatheter delivery. Protein-glycation limits the durability of BHV, contributing to device failure, often requiring reoperation after only a decade or less of functionality. This problem is addressed by modifying BHV leaflets with poly-2-methyl-2-oxazoline, effectively mitigating glycation and serum protein infiltration and enhancing biocompatibility.